Nearly 1 out of every 100 children admitted to the PICU meet the American European Consensus Conference criteria [1] for acute lung injury (ALI) or acute respiratory distress syndrome (ARDS), and ...

In the U.S. alone, ARDS affects over 500,000 patients per year, or roughly 10% of all ICU admissions. With no effective pharmacological therapies currently available for ARDS and its high mortality ...

BioAegis Therapeutics Receives FDA Fast Track Designation for Lead Product, Recombinant Human Gelsolin, for the Treatment of Acute Respiratory Distress Syndrome (ARDS)Fast Track status enables ...

BioAegis’ lead product, rhu-pGSN, is currently being studied in a 600-patient global Phase 2 trial for patients with moderate to severe Acute Respiratory Distress Syndrome (ARDS). This project has ...

Chart Industries Inc. and Flowserve Corp. agreed June 4 to combine in an all-stock merger, creating a differentiated leader in industrial process technologies. The combined company is expected to be ...

Acute respiratory distress syndrome (ARDS) remains a significant hazard to human health and is clinically challenging because there are no prognostic biomarkers and no effective pharmacotherapy. The ...

Assessment for Race National B is broken down into two elements, a written exam and practical exam – they compromise the ARDS (Association of Racing Drivers Schools) test. The former will review ...

Data Selection: The epidemiology of acute respiratory distress syndrome in adults and children, lung morphogenesis, and postnatal lung growth and development are reviewed. The pathophysiology of ...

Background There are no evidence-based recommendations for surfactant use in late preterm (LPT) and term infants with respiratory distress syndrome (RDS). Objective To investigate the safety and ...

Objective To compare the efficacy of continuous positive airway pressure (CPAP) versus usual care for prehospital patients with severe respiratory distress. Methods We conducted a parallel group, ...